Logo image of TIL

INSTIL BIO INC (TIL) Stock Fundamental Analysis

NASDAQ:TIL - Nasdaq - US45783C2008 - Common Stock - Currency: USD

30.33  -4.07 (-11.83%)

After market: 30.8 +0.47 (+1.55%)

Fundamental Rating

2

TIL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. TIL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TIL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TIL had negative earnings in the past year.
TIL had a negative operating cash flow in the past year.
In the past 5 years TIL always reported negative net income.
In the past 5 years TIL always reported negative operating cash flow.
TIL Yearly Net Income VS EBIT VS OCF VS FCFTIL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

With a decent Return On Assets value of -32.86%, TIL is doing good in the industry, outperforming 63.98% of the companies in the same industry.
TIL has a better Return On Equity (-53.85%) than 63.98% of its industry peers.
Industry RankSector Rank
ROA -32.86%
ROE -53.85%
ROIC N/A
ROA(3y)-39.98%
ROA(5y)-40.08%
ROE(3y)-52.91%
ROE(5y)-50.43%
ROIC(3y)N/A
ROIC(5y)N/A
TIL Yearly ROA, ROE, ROICTIL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

TIL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TIL Yearly Profit, Operating, Gross MarginsTIL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -5K -10K -15K -20K -25K

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, TIL has more shares outstanding
Compared to 5 years ago, TIL has less shares outstanding
TIL has a worse debt/assets ratio than last year.
TIL Yearly Shares OutstandingTIL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
TIL Yearly Total Debt VS Total AssetsTIL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -2.20, we must say that TIL is in the distress zone and has some risk of bankruptcy.
TIL's Altman-Z score of -2.20 is in line compared to the rest of the industry. TIL outperforms 53.23% of its industry peers.
A Debt/Equity ratio of 0.58 indicates that TIL is somewhat dependend on debt financing.
The Debt to Equity ratio of TIL (0.58) is worse than 74.73% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF N/A
Altman-Z -2.2
ROIC/WACCN/A
WACCN/A
TIL Yearly LT Debt VS Equity VS FCFTIL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

TIL has a Current Ratio of 30.33. This indicates that TIL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 30.33, TIL belongs to the top of the industry, outperforming 97.49% of the companies in the same industry.
TIL has a Quick Ratio of 30.33. This indicates that TIL is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 30.33, TIL belongs to the best of the industry, outperforming 97.49% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 30.33
Quick Ratio 30.33
TIL Yearly Current Assets VS Current LiabilitesTIL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 36.77% over the past year.
EPS 1Y (TTM)36.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, TIL will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.58% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y46.44%
EPS Next 2Y23.59%
EPS Next 3Y11.37%
EPS Next 5Y13.58%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TIL Yearly Revenue VS EstimatesTIL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2029 2030 2031 2032 100M 200M 300M 400M
TIL Yearly EPS VS EstimatesTIL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TIL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TIL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TIL Price Earnings VS Forward Price EarningsTIL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TIL Per share dataTIL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.59%
EPS Next 3Y11.37%

More info and screens

0

5. Dividend

5.1 Amount

TIL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INSTIL BIO INC

NASDAQ:TIL (6/5/2025, 8:00:01 PM)

After market: 30.8 +0.47 (+1.55%)

30.33

-4.07 (-11.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners78.56%
Inst Owner Change0.17%
Ins Owners10.98%
Ins Owner Change0%
Market Cap198.96M
Analysts82.5
Price Target115.94 (282.26%)
Short Float %7.52%
Short Ratio1.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.65%
Min EPS beat(2)-65.34%
Max EPS beat(2)44.04%
EPS beat(4)2
Avg EPS beat(4)-15.92%
Min EPS beat(4)-66.31%
Max EPS beat(4)44.04%
EPS beat(8)4
Avg EPS beat(8)-62.34%
EPS beat(12)6
Avg EPS beat(12)-53.79%
EPS beat(16)6
Avg EPS beat(16)-43.91%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.29%
EPS NQ rev (1m)6.19%
EPS NQ rev (3m)28.33%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.37
P/tB 1.37
EV/EBITDA N/A
EPS(TTM)-11.97
EYN/A
EPS(NY)-11.34
Fwd EYN/A
FCF(TTM)-8.46
FCFYN/A
OCF(TTM)-6.94
OCFYN/A
SpS0
BVpS22.09
TBVpS22.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.86%
ROE -53.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.98%
ROA(5y)-40.08%
ROE(3y)-52.91%
ROE(5y)-50.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 30.33
Quick Ratio 30.33
Altman-Z -2.2
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1316.52%
Cap/Depr(5y)4909.14%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.51%
EPS Next Y46.44%
EPS Next 2Y23.59%
EPS Next 3Y11.37%
EPS Next 5Y13.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y30.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year60.91%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y75.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y71.47%
OCF growth 3YN/A
OCF growth 5YN/A